NZ 687
Alternative Names: NZ-687; NZ-687-SRLatest Information Update: 02 Feb 2022
At a glance
- Originator Nippon Zoki
- Class Analgesics; Anti-inflammatories; Antipyretics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cancer pain
Most Recent Events
- 21 Dec 2021 Efficacy and safety data from a phase III trial in cancer pain released by Nippon-Zoki (JapicCTI-184143)
- 30 Oct 2020 Nippon Zoki completes phase III trial in Cancer pain (Treatment-naive) in Japan (PO) (JapicCTI-184143)
- 05 Oct 2018 Phase-III clinical trials in Cancer pain (Treatment-naive) in Japan (PO) (JapicCTI-184143)